Alasdair Milton, PhD

Alasdair is a leader in KPMG’s Precision Medicine and Advanced Therapies practice. He has over 20 years experience in strategy consulting and market research specializing in inorganic growth, commercial strategy and portfolio optimization for biopharmaceutical, genomic, diagnostic and health system clients, as well as private investors. Alasdair has also worked with numerous pre-revenue biotechnology companies to help them shape their equity story in preparation for capital raise. As a trained cancer biologist Alasdair helps clients across R&D, manufacturing and supply chain, medical affairs and commercial operations solve complex business problems that require deep scientific and technical knowledge, and he has worked across multiple therapeutic areas, including CNS, hematology, immunology, infectious disease, metabolic diseases, oncology, respiratory, women’s health, as well as rare and ultra-rare diseases. A particular focus is in advanced therapies such as cell therapies, gene therapies, mRNA, RNAi and ASOs across both in vivo and ex vivo approaches where he has supported biopharmaceutical, Life Science tools and CDMO clients in their manufacturing and supply chain strategies and commercial launches. He has also led numerous commercial due diligence and inorganic growth strategy projects for both corporate and private investors looking to deploy capital in the advanced therapies space.